IP Library Granted Patent US 7,452,905
Granted Patent B2
US 7,452,905 · App. 10/402,006 · Granted Nov 18, 2008

Phenylalanine derivatives

Assignee: Ajinomoto Co., Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,452,905
App. No.
10/402,006
Granted
Nov 18, 2008
Kind
B2
Abstract

Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the α 4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which α 4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

Claims (40)

1. A phenylalanine compound of formula (1) or a pharmaceutically acceptable salt thereof:

wherein A represents one of formula (26-2), (26-3), or (27):

wherein each of Ra, Rb, Rc, and Rd represents a hydrogen atom,

R2 and R2′ together form an alkylene group having 4 to 6 carbon atoms,

each of R3 and R4 represents a hydrogen atom, a lower alkyl group, a lower alkoxyl group, a lower alkoxycarbonyl group, a lower alkylcarbonyl group, a cyano group, or a nitro group,

B represents a hydroxyl group or a lower alkoxyl group,

E represents a hydrogen atom,

D represents a phenyl group which may be substituted with one or more substituents selected from the group consisting of halogeno, alkoxy, alkyl, hydroxyl, halogenoalkyl, halogenoalkoxy, and lower-alkylsulfonylamino,

T represents C(═O), and

J and J′ may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkyloxy group or nitro group.

2. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein A represents the formula (26-2), and

D represents a phenyl group.

3. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 2 , wherein A represents the formula (26-2).

4. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein A represents the formula (26-3).

5. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein D represents a 2,6-dichlorophenyl group, or a 2,6-dichloro-4-lower-alkylsulfonylamino-phenyl group.

6. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein A represents formula (27):

wherein R2 and R2′ are as defined above, and

J and J′ represent a hydrogen atom.

7. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 6 , wherein D represents a 2,6-dichlorophenyl group, or a 2,6-dichloro-4-lower-alkylsulfonylamino-phenyl group.

8. A phenylalanine compound or pharmaceutically acceptable salt thereof, which is selected from the group consisting of the following structural formulae

and pharmaceutically acceptable salts thereof.

9. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein each of J and J′ is a hydrogen atom.

10. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein A represents formula (26-2) and each of J and J′ is a hydrogen atom.

11. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein A represents formula (26-3) and each of J and J′ is a hydrogen atom.

12. The phenylalanine compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein A represents formula (27).

13. A composition, comprising a phenylalanine compound or a pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.

14. The composition of claim 13 , wherein A represents the formula (26-2), and

D represents a phenyl group.

15. The composition of claim 14 , wherein A represents the formula (26-2).

16. The composition of claim 13 , wherein A represents the formula (26-3).

17. The composition of claim 13 , wherein D represents a 2,6-dichlorophenyl group or a 2,6-dichloro-4-lower-alkylsulfonylamino-phenyl group.

18. The composition of claim 13 , wherein A represents formula (27):

wherein R2 and R2′ are as defined above, and

J and J′ represent a hydrogen atom.

19. The composition of claim 18 , wherein D represents a 2,6-dichlorophenyl group or a 2,6-dichloro-4-lower-alkylsulfonylamino-phenyl group.

20. A composition, comprising a phenylalanine compound or a pharmaceutically acceptable salt thereof according to claim 8 and a pharmaceutically acceptable carrier.

21. The composition of claim 13 , wherein each of J and J′ is a hydrogen atom.

22. The composition of claim 13 , wherein A represents formula (26-2) and each of J and J′ is a hydrogen atom.

23. The composition of claim 13 , wherein A represents formula (26-3) and each of J and J′ is a hydrogen atom.

24. The composition of claim 13 , wherein A represents formula (27).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2016
From: AJINOMOTO CO., INC.
To: EA PHARMA CO., LTD.
Reel/Frame 039094/0087 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2003
From: SUZUKI, NOBUYASU; YOSHIMURA, TOSHIHIKO; IZAWA, HIROYUKI; SAGI, KAZUYUKI; MAKINO, SHINGO; NAKANISHI, EIJI; MURATA, MASAHIRO; TSUJI, TAKASHI
To: AJINOMOTO CO., INC.
Reel/Frame 013918/0851 →
Priority Claims (2)
JP 2000-299490 · Sep 29, 2000 · national
JP 2001-041885 · Feb 19, 2001 · national
Continuity (2)
Continuation PCTJP010848900 · Sep 28, 2001
Related Publication 20030220318A1 · Nov 27, 2003